University Hospital of Lille [CHU Lille]

The University Hospital of Lille (CHU-Lille) is a university hospital centre with a total capacity of more than 3000 beds and is made up of 14 specialist hospitals, in the European metropolis of Lille (Hauts-de-France), and it is affiliated with ULille. Together with the Eurasanté Park and the University of Lille, it constitutes one of the largest health campuses in Europe and its Faculty of Medicine is the largest in France with more than 12000 students. For more than 10 years, it is ranked among the three best hospitals in France¹ for care (2^nd this year), the 3^rd best one for scientific publications (6123 articles between 2015 and 2018), and the 4^th for clinical trials (more than 8000 patients included each year).

The participating team is leaded by Pr. David Devos. The team has medical expertise in infectious diseases of Pr. Julien Poissy (Covid-19 in intensive care unit) and Dr. Emmanuel Faure (Covid-19 in medical units) as well as in virology and diagnosis (PCR and serology) thanks to Dr. Enagnon Kazali Alidjinou and Dr. Ilka Engelmann. Prof. Alain Duhamel is leading the department of Biostatistics of the CHU-Lille also participating in CorDial-S.

¹Le classement des meilleurs hôpitaux de France 2015  (consulté le 23 juillet 2016)

1. C. Moreau, J.A. Duce, O. Rascol, J.C. Devedjian, D. Berg, D. Dexter, Z.I. Cabantchik, A.I. Bush, D. Devos. (2018). FAIRPARK-II study group. Iron as a therapeutic target for Parkinson's disease. Mov. Disord. 33, 568-574. (IF 8.324)
2. D. Devos, C. Moreau, J.C. Devedjian, J. Kluza, M. Petrault, C. Laloux, A. Jonneaux, G. Ryckewaert, G. Garçon, N. Rouaix, A. Duhamel, P. Jissendi, K. Dujardin, F. Auger, L. Ravasi, L. Hopes, G. Grolez, W. Firdaus, B. Sablonnière, I. Strubi-Vuillaume, N. Zahr, A. Destée, J.C. Corvol, D. Pöltl, M. Leist, C. Rose, L. Defebvre, P. Marchetti, Z.I. Cabantchik, R. Bordet. (2014). Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal. 21, 195-210. (IF 5.828)
3. C. Moreau, S. Meguig, J.C. Corvol, J. Labreuche, F. Vasseur, A. Duhamel, A. Delval, T. Bardyn, J.C. Devedjian, N. Rouaix, G. Petyt, C. Brefel-Courbon, F. Ory-Magne, D. Guehl, A. Eusebio, V. Fraix, P.J. Saulnier, O. Lagha-Boukbiza O, F. Durif, M. Faighel, C. Giordana, S. Drapier, D. Maltête, C. Tranchant, J.L. Houeto, B. Debû, J.P. Azulay, F. Tison, A. Destée, M. Vidailhet, O. Rascol, K. Dujardin, L. Defebvre, R. Bordet, B. Sablonnière, D. Devos. (2015). Parkgait-II Study Group. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. Brain 138, 1271-1283. (IF 11.814)
4. C. Moreau, A. Delval, L. Defebvre, K. Dujardin, A. Duhamel, G. Petyt, I. Vuillaume, J.C. Corvol, C. Brefel-Courbon, F. Ory-Magne, D. Guehl, A. Eusebio, V. Fraix, P.J. Saulnier, O. Lagha-Boukbiza, F. Durif, M. Faighel, C. Giordana, S. Drapier, D. Maltête, C. Tranchant, J.L. Houeto, B. Debû, B. Sablonniere, J.P. Azulay, F. Tison, O. Rascol, M. Vidailhet, A. Destée, B.R. Bloem, R. Bordet, D. Devos. (2012). Parkgait-II study group. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 11, 589-596. (IF 28.755)
5. C. Moreau, L. Defebvre, A. Destée, S. Bleuse, F. Clement, J.L. Blatt, P. Krystkowiak, D. Devos. (2008). STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology 71, 80-84. (IF 8.055)